27 7 月, 2022

Toyota: Yamato Transport and CJPT to Begin Studying Standardization and Commercialization of Cartridge Batteries

TOKYO, Jul 27, 2022 - (JCN Newswire via SEAPRWire.com) - Yamato Transport Co., Ltd. (Yamato Transport) and Commercial Japan Partnership Technologies Corporation (CJPT) have announced today that they will begin studying the standardization and commercialization of replaceable and rechargeable cartridge batteries as part of energy management efforts for achieving a carbon neutral society.Cartridge battery useThe introduction of commercial battery electric vehicles (BEVs) poses several challenges, including recharging times that are longer than refueling times for conventional gasoline and diesel vehicles, as well as increased logistics downtime (when vehicles and cargo are at a standstill) due to numerous vehicles recharging at or around the same time. The introduction of commercial BEVs is also expected to impose an increasing burden on society as a whole, such as by increasing peak electricity demand at business sites due to concentrated recharging by numerous non-operating vehicles.To solve these issues, Yamato Transport and CJPT will begin studying the practical application of detachable and portable cartridge batteries based on their following merits.1. Able to reduce the cost of BEV introduction: The cost can be reduced by limiting battery capacity--and, thus, the total amount of batteries--to match actual driving-range needs.2. Able to reduce the recharging burden: The burden related to the installation of recharging infrastructure can be reduced.3. Able to reduce logistics downtime: Battery replacement can reduce vehicle recharging time.4. Able to level electricity demand: Replacement batteries can be recharged while vehicles are in operation, reducing peak electricity demand.Furthermore, CJPT intends to advance plans for commercial BEVs that cartridge batteries can power. The company envisions that commonizing cartridge batteries and recharging systems for vehicles ranging from BEV mini-commercial vans to BEV light-duty trucks will reduce the cost of commercial BEVs and encourage their widespread use. As an energy-management solution, the company seeks to propose ways to achieve battery use that matches actual use requirements.Meanwhile, Yamato Transport aims to build a green delivery eco-system that includes its transport and delivery partners by co-creating with communities a cartridge battery-based electricity utilization scheme. In addition to promoting the use of green power by eliminating the gap between renewable energy generation peaks and the timing of recharging commercial BEVs, the company also intends to study ways to increase the resilience of electric energy supply communities, such as by delivering cartridge batteries in times of disaster to areas where it is difficult to maintain electric power infrastructure.The two companies are open to considering collaboration with new partners for the standardization and commercialization of cartridge batteries toward popularizing electrified vehicles as a way to contribute to the achievement of a carbon-neutral society.Sustainable Development GoalsToyota Motor Corporation works to develop and manufacture innovative, safe and high-quality products and services that create happiness by providing mobility for all. We believe that true achievement comes from supporting our customers, partners, employees, and the communities in which we operate. Since our founding over 80 years ago in 1937, we have applied our Guiding Principles in pursuit of a safer, greener and more inclusive society. Today, as we transform into a mobility company developing connected, automated, shared and electrified technologies, we also remain true to our Guiding Principles and many of the United Nations' Sustainable Development Goals to help realize an ever-better world, where everyone is free to move.SDGs Initiatives: https://global.toyota/en/sustainability/sdgs/ Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

8 7 月, 2022

Isuzu, DENSO, Toyota, Hino, and CJPT to Start Planning and Foundational Research on Hydrogen Engines for Heavy-Duty Commercial Vehicles

TOKYO, Jul 8, 2022 - (JCN Newswire via SEAPRWire.com) - Isuzu Motors Limited (Isuzu), DENSO Corporation (DENSO), Toyota Motor Corporation (Toyota), Hino Motors, Ltd. (Hino), and Commercial Japan Partnership Technologies Corporation (CJPT) announced today that they have started planning and foundational research on hydrogen engines for heavy-duty commercial vehicles with the aim of further utilizing internal combustion engines as one option to achieve carbon neutrality.On the road to carbon neutrality, there are various powertrain options to meet customers' demands, including HEVs, BEVs, and FCEVs, in accordance with the differences in energy conditions in different countries and diversified customer uses. Hydrogen engines are one such option. The hydrogen-powered Corolla(1) has participated in the Super Taikyu Series(2) since May 2021, and hydrogen engine technology is evolving. In addition, efforts toward achieving a hydrogen society are further accelerating, such as the increase in the number of partners in producing, transporting, and using hydrogen.CO2 reduction in transportation and logistics by heavy-duty commercial vehicles, an important piece of infrastructure that supports people's lives, is a social issue that needs to be addressed together with partners who share a common vision toward achieving a carbon neutral society. Isuzu, DENSO, Toyota, Hino, and CJPT believe that hydrogen engines are one solution to this issue, and will utilize the technologies and know-how each company has accumulated to study the potential of hydrogen engines in heavy-duty commercial vehicles.The five companies will contribute to creating an even-better society by expanding the options available for achieving carbon neutrality.(1) ORC ROOKIE GR Corolla H2 Concept(2) "Super Taikyu Series 2021 Powered by Hankook," "ENEOS Super Taikyu Series 2022 Powered by Hankook" Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

18 3 月, 2022

Sierra Space Signs Memorandum of Understanding with Mitsubishi Heavy Industries

LOUISVILLE, CO, Mar 18, 2022 - (JCN Newswire via SEAPRWire.com) - Sierra Space, a leading commercial space company with 1,100 employees, more than 500 missions and over 30 years of space flight heritage, and Mitsubishi Heavy Industries (MHI), a leading company in the space development industry in Japan, announced that the companies have jointly signed a new Memorandum of Understanding (MOU).Orbital Reef by 2035 - Sierra SpaceThe MOU agreement outlines plans for Sierra Space and MHI to collaborate on a wide range of technologies regarding the development of Orbital Reef, a commercially developed, owned and operated space station to be built in low Earth orbit (LEO) by investors Sierra Space and Blue Origin.Sierra Space and MHI have commenced work on incorporating MHI expertise in the development of Orbital Reef, bringing in technologies and expertise from MHI's years of experience with the International Space Station (ISS) program."At Sierra Space we are building a platform in space to benefit life on Earth," said Tom Vice, Sierra Space CEO. "We are proud to formalize a long-standing relationship with MHI and look forward to leveraging its considerable technological expertise, as we continue building Orbital Reef and the next generation of space transportation.""MHI is very excited to collaborate with Sierra Space and use MHI's technologies and experience earned over years to contribute to the development of Orbital Reef, the program led by Sierra Space, Blue Origin and their international partners," said Tomoe Nishigaya, Vice President and Senior General Manager of Space Systems at MHI. "We look forward to further collaboration with Sierra Space as to how MHI's technologies, products and services may provide better experience for users and customers of the space station. Additionally, MHI plans to cooperate with JAXA and other aerospace companies in Japan, leveraging strong relationships built through participation to the ISS program."About Sierra SpaceSierra Space products and programs are working towards a more accessible space economy. The company is rapidly advancing toward the launch of the world's only winged commercial spaceplane, the Dream Chaser. As the next generation of space transportation, the Dream Chaser will perform cargo supply and return missions for NASA, set to begin in late 2022, delivering up to 12,000 pounds of cargo to the International Space Station (ISS) at a time. The return journey will carry critical data, generated by ISS researcher experiments, enabling earth-bound scientists to benefit from much faster access to these unique results. Dream Chaser is a reusable spaceplane, uniquely capable of a smooth 1.5 low-g re-entry for crew and cargo transportation with the ability to land on existing commercial runways worldwide.Sierra Space is the developer of the Large Integrated Flexible Environment (LIFE) Habitat, a modular, three-story commercial habitation and science platform. The unique structure will provide opportunities for multiple businesses including manufacturing, pharmaceuticals, and other sectors, to optimize zero gravity benefits. The LIFE Habitat will be able to be deployed in low-Earth orbit, on the lunar surface, or lunar orbit, and as a transport vehicle to Mars. Both Dream Chaser and LIFE Habitat will launch using conventional rocket propulsion systems.The Dream Chaser spaceplane and LIFE platform are central components of the joint partnership Orbital Reef commercial space station and mixed-use business park being developed in partnership with Blue Origin.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, logistics & infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

15 3 月, 2022

Mitsubishi Motors Krama Yudha Sales Indonesia Signs MoU with Pos Indonesia, Haleoya Power, Gojek and DHL Supply Chain Indonesia to Do a Pilot Study on Commercial Usage of Electric Vehicles

TOKYO, Mar 15, 2022 - (JCN Newswire via SEAPRWire.com) - Mitsubishi Motors Corporation announced that PT Mitsubishi Motors Krama Yudha Sales Indonesia (MMKSI) signed a Memorandum of Understanding (MoU) with four companies in Indonesia to conduct a pilot study on commercial usage of a kei-car(1) class electric commercial vehicle (EV), Minicab-MiEV, a model currently marketed in Japan.Minicab-MiEV to be provided to the four companies Under the MoU terms, MMKSI will provide the Minicab-MiEV to the four companies - PT Pos Indonesia, PT Haleyora Power, Gojek and DHL Supply Chain Indonesia-for six months(2) for research and utilization in their logistics operations in Jabodetabek area. This study aims to understand and explore commercial EV applications, by verifying actual usage data, including mileage, charge history and delivery routes. "We highly appreciate our leading company partners, PT Pos Indonesia, PT Haleyora Power, Gojek and DHL Supply Chain Indonesia, as well as the Government of Indonesia who enthusiastically supported this joint study," said Naoya Nakamura, president director PT MMKSI. "Through this study, we hope to explore broader use of Mitsubishi Motors' electric commercial vehicles in Indonesia." (1) Kei-car is a vehicle category in Japan for microcars.(2) Gojek will utilize Minicab-MiEV for joint study for more than six months. About Mitsubishi MotorsMitsubishi Motors Corporation (TSE:7211), MMC--a member of the Alliance with Renault and Nissan--, is a global automobile company based in Tokyo, Japan, which has more than 30,000 employees and a global footprint with production facilities in Japan, Thailand, Indonesia, mainland China, the Philippines, Viet Nam and Russia. MMC has a competitive edge in SUVs, pickup trucks and plug-in hybrid electric vehicles, and appeals to ambitious drivers willing to challenge convention and embrace innovation. Since the production of our first vehicle more than a century ago, MMC has been a leader in electrification--launched the i-MiEV -- the world's first mass-produced electric vehicle in 2009, followed by the Outlander PHEV --the world's first plug-in hybrid electric SUV in 2013. MMC announced a three-year business plan in July 2020 to introduce more competitive and cutting-edge models, including the Eclipse Cross (PHEV model), the all-new Outlander and the all-new Triton/L200.For more information on MMC, please visit the company's website athttps://www.mitsubishi-motors.com/en/ Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

7 3 月, 2022

Three companies in commercial trials to deliver goods to ships using drones

4 3 月, 2022

MHI Announces Changes in Executive-level Personnel

TOKYO, Mar 4, 2022 - (JCN Newswire via SEAPRWire.com) - Mitsubishi Heavy Industries Aero Engines, Ltd. (MHIAEL), a group company of Mitsubishi Heavy Industries, Ltd. (MHI) has announced the appointment of Masanori Ushida as President & Chief Executive Officer (CEO), effective April 1, 2022. He succeeds Katsuyuki Shimauchi, who will continue to serve as Member of the Board of MHIAEL after serving as the first President & CEO of MHIAEL for more than seven years.Mr. Ushida assumes the role of President & CEO after serving as Member of the Board and Senior Vice President of Commercial Engines since October 2020. He brings his more than 30 years of experience in MHI's aerospace business which includes multiple leadership roles ranging from manufacturing engineering, engine design to program management. He has also successfully grown MHIAEL's commercial engine maintenance, repair and overhaul (MRO) business to become one of the company's core businesses.During his tenure as President & CEO, Mr. Shimauchi has successfully led the establishment of MHIAEL by ways of company split from MHI in October 2014 and managed to grow its revenues in three folds by 2019. He has also successfully navigated the company through one of the most challenging periods in aerospace history and formed a pathway for continued and further growth of the business including establishment of MHIAEL's second production site in Nagasaki.Commenting on the appointment, Katsuyuki Shimauchi said, "The time has now come for me to step down and hand over to the next generation. Mr. Ushida is a tested leader who has successfully led our commercial engine programs with deep industry expertise and a fundamental understanding of our business. He also has a proven track record of building strong relationships with our stake holders, including customers and business partners. This is a crucial time for aero engine business, and I am very confident that he will help advance MHIAEL's further growth."Masanori Ushida added, "I am honored to take up this opportunity at such an important time for MHIAEL. Under Mr. Shimauchi's strong leadership, MHI's aero engine business has grown significantly and strengthened our position in the aviation industry. Inheriting his great achievements, I look forward to continue working with our customers, business partners and our team to realize our full potential." Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

1 11 月, 2021

Thai Union Feedmill (SET: TFM) lists, aims to lead aquaculture and commercial animal feed sector

BANGKOK, Nov 1, 2021 - (ACN Newswire via SEAPRWire.com) - Thai Union Feedmill PCL (SET: TFM), a manufacturer and distributor of aquaculture and commercial animal feeds, is confident of positive investor response following the company's listing on the Stock Exchange of Thailand (SET) today. Determined to be the leader in the aquaculture and commercial animal feed business, TFM aims to grow in overseas markets through cooperative agreements, joint ventures with trading partners, and direct exports in order to support food security for Asia's future.Bunluesak Sorajjakit, TFM Chief Executive Officer, said the Company, which began trading in the Agribusiness sector under the symbol "TFM", has over 20 years experience in the industry and accumulated know-how that has led to innovations in production processes. The Company has become a leader in the production and distribution of aquaculture and commercial animal feeds in Thailand, offering quality and widely-known branded products. Sorajjakit is confident that TFM's IPO will attract widespread interest among investors.Following the Company's listing on the SET, TFM is prepared for continual sustainable growth and determined to take the leadership role in the aquaculture and commercial animal feed business sector. Between 2021 and 2023, it expects to spend the proceeds from the sale of shares (1,177.4 million baht) in the following activities:i. Expand production and distribution of aquaculture feeds through Indonesia-based subsidiary TUKL by adding two lines of production, which will increase capacity by 36,000 tons per year, requiring an investment of no more than 250 million baht by 2023;ii. Repay loans of between 250-350 million baht by March 2022 to reduce the debt-to-equity (D/E) ratio to less than 1 time (x), after the IPO; andiii. Use the remainder as working capital.Moreover, as a policy, TFM intends to pay dividends twice a year, amounting to no less than 50 percent of the net profit per the consolidated financial statements after reduction of all categories of reserves according to company rules and legal requirements.The TFM CEO adds that the Company is determined to expand its operations to overseas markets with appropriate business models deemed beneficial. These are:I. Technical support to the Indian partnerAn agreement of technical cooperation with Avanti Feeds Limited (AVANTI), India's major shrimp feed producer, allows it to use TFM's trade name and feed formulae to produce and sell shrimp feed in India;II. Overseas JVs with partnersi. TFM joined with strategic partners to form PT Thai Union Karisma Lestari Co., Ltd. (TUKL), a subsidiary to produce and distribute aquaculture feeds in Indonesia. The two strategic partners are PT MSK, a major producer of frozen seafood in Indonesia, and AVANTI. TFM, PT MSK, and AVANTI hold 65 percent, 25 percent, and 10 percent of TUKL's paid-up capital respectively. ii. TFM formed a joint venture AMG-Thai Union Feedmill (Private) Limited (AMG-TFM) with a strategic partner in Pakistan. The Pakistani partner AMG is the country's major producer of aquaculture feed. AMG holds 49 percent of shares in the new company while TFM holds 51 percent as of June 30, 2021. AMG-TFM produces 7,000 tons of fish feed per year and plans to increase capacity to 15,000 tons per year within 2021. The joint venture has started commercial operations and recognized revenues with net profit since the 2nd quarter of 2021;III. Direct exports to various foreign countries, including Malaysia, Maldives, Myanmar, Pakistan and Sri Lanka.IV. Domestic market expansion, TFM plans to develop new business and continues efforts in maintaining its competitiveness as an industry leader. The Company is the first in Thailand to produce and distribute feeds in form of pellets for sea bass to replace the use of fresh prey, and also a leading producer and distributor of feeds for giant sea bass. The Company has also launched products under its "fighting" brand through a marketing campaign to expand its customer base to more diverse segments as the demand for fish feed is on the rise. The Company has set its sights on promoting feeds for other fish species and has been putting in research and development efforts on feeds for other aquatic species, such as crab and gourami. TFM envisions a growth opportunity in the commercial animal feed sector that should help support food security in Asia.Pichet Sithi-amnuay, managing director of Bualuang Securities, the financial advisor and underwriter of the Company's IPO, says that TFM, with more than 20 years of experience and expertise, a highly qualified staff, a strong capital base and access to innovations, manages to improve its competitiveness and even raise the standards of the industry as a whole. TFM is capable of producing products of high quality with consistency and high performance, contributing to the healthy growth of aquatic species. TFM can also produce a range of products encompassing the entire life cycle needs of aquaculture at competitive prices. TFM's products and brands have earned customers' trust and satisfied their diverse demands over a long period of time.For these reasons, TFM is in a prime position to pursue growth opportunities in both local and overseas markets through expansion in the production of feeds for aquatic and other types of animals. Other channels of overseas expansion include entering into cooperative agreements with local strategic partners or joint ventures to set up production bases, which will contribute to the Company's sustainable growth. Thus far, TFM has attracted great interest from institutional and retail investors. It is a clear sign of confidence that TFM shares are of strong fundamentals which should gain wide acceptance from investors.Released by Public Relations Dept., MT Multimedia Co., Ltd. for Thai Union Feedmill Public Company LimitedFor more information, please contact: Ornanong Pattaravejakul (Fah)Tel: +66-99-194-6597, +66-86-801-8888, Email: ornanong.p@mtmultimedia.com Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

17 8 月, 2021

Quantron Supports IKEA’s Emissions-free Delivery

HONG KONG, Aug 17, 2021 - (ACN Newswire via SEAPRWire.com) - Quantron, strategic partner of Ev Dynamics, delivers 30 electric vans to IKEA Austria.Andreas Haller, founder and CEO of Quantron AG (left), hands over a symbolic key for the delivered vehicles to Claes Lindgren, Country Customer Fulfillment Manager IKEA Austria (right)Quantron AG, handed over the first set of 100% emission-free vans to IKEA Austria, this week. The international furniture company IKEA has set itself the goal of becoming climate-positive by 2030. The e-mobility specialist Quantron supports IKEA in this mission and supplies the IKEA logistics center near Vienna with 30 environmentally friendly e-vehicles. The Germany based Quantron AG is strategic partner of Ev Dynamics.Quantron's first all-electric Q-Light was already used for extensive testing at the logistics center in June. With a range of at least 170 km, a drive power of 100 kW and a maximum charging power of 70 kW, the e-transporters are ideally equipped for routes between IKEA locations and customers' delivery addresses. Initially, the vehicles will be used for deliveries to all 23 of Vienna's municipal districts and within a 30 km radius of the logistics center. Andreas Haller, founder and CEO of Quantron AG: "We are pleased to be able to support IKEA with our knowledge and expertise in this important step towards emission-free delivery. Quantron is proud to help companies like IKEA with our many years of e-mobility experience and our international network to make the switch to emission-free freight transport."Miguel Valldecabres Polop, CEO of Ev Dynamics, said: "Ev Dynamics and Quantron entered into a share swap agreement on 29 July 2021. Ev Dynamics is proud as investor and strategic partner for the win of this new business opportunity for Quantron AG."About Ev Dynamics (Holdings) Limited (Stock Code: 476)Ev Dynamics (Holdings) Limited is a pioneer and a prominent player in China's new energy commercial vehicles market, as well as a whole-vehicle manufacturer of specialty passenger vehicles and new energy passenger vehicles. It is an integrated driving and logistics solutions provider with a solid technological foundation in diverse areas including new energy platform power systems and their key components. The Group has a production base in Chongqing and it has developed its sales network in Mainland China, Hong Kong, Asia Pacific and South America. About Quantron AGQuantron AG is a provider of clean battery and hydrogen-powered e-mobility systems for commercial vehicles such as trucks, buses and vans. In addition to new electric vehicles, the wide range of services offered by the innovative solutions include the electrification of used and existing vehicles, the creation of individual overall concepts including the appropriate charging infrastructure as well as rental, financing and leasing services and driver training. Quantron AG also sells batteries and integrated customised electrification concepts to manufacturers of commercial vehicles, machinery and intralogistics vehicles. The German company from Augsburg in Bavaria is a pioneer and innovation driver for e-mobility in passenger, transport and freight traffic.You can find more information at www.quantron.netVisit the Quantron AG on its social media channels on LinkedIn ( https://www.linkedin.com/company/quantron-ag ) and YouTube ( https://www.youtube.com/channel/UCDQ-CKkS8XMHcJ9Ze-6UVNA )Media EnquiryStrategic Financial Relations LimitedVicky Lee +852 2864 4834 vicky.lee@sprg.com.hkPhoebe Leung +852 2114 4172 phoebe.leung@sprg.com.hkEddie Li +852 2114 4170 eddie.li@sprg.com.hkWebsite: www.sprg.com.hkQuantron AGVolker Seitz 0049-821-789840-86 press@quantron.netYou can find the original photo in low and high resolution here: Press releases from Quantron AG (https://www.quantron.net/en/q-news/pr-berichte/) Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

13 8 月, 2021

TOT BIOPHARM 2021 Interim Revenue Surges 78% to RMB23.13 million

HONG KONG, Aug 13, 2021 - (ACN Newswire via SEAPRWire.com) - TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Group"; stock code: 1875.HK), a biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs and therapies, announced today its unaudited interim results for the six months ended 30 June 2021.KEY MILESTONES IN 2021 1HIn the first half of 2021, on the back of by national policies and driven by innovative R&D, the oncology drug market in China boomed and continued to gather growth momentum. The Group continued to implement its strategic plans drawing on its own strengths and competitive advantages, striving to become a leading player in the domestic ADC market. The Group speeded up R&D of ADC drugs and industrial planning and grasped market opportunities, enabling it to achieve breakthroughs in the realm of innovative drug CDMO/CMO.Approval for Two Products Launching in the Market:-- TOZ309 (temozolomide capsules) was approved for launch in China by the NMPA in May 2021. It is a first-line medication for newly diagnosed and recurrent glioma as well as recurrent anaplastic astrocytoma. TOZ309 is the first self-developed chemical drug of TOT BIOPHARM. Together with other pharmaceutical companies in China to hasten market penetration of the product. It will at the same time prepare for renewal of the fourth round of drugs for centralized procurement in China in 2022.-- TOM218 (Megaxia(R) - megestrol acetate oral suspension) is imported by the Group, it owns the exclusive agency of the drug in mainland China, Hong Kong and Macau. The drug can alleviate the cachexia status of AIDS and cancer patients, including loss of appetite and body weight, and nausea and vomiting that sometimes occur. Compared to the solid dosage forms, oral suspensions can reduce the discomfort of patients in swallowing. Megaxia(R) had been approved for sale in the United States in 2014 and is the first high concentration megestrol acetate oral suspension approved for sale in China. Major milestones of key products in clinical trial-- Core product TAB008 - Application for Marketing Approval Submitted and Being Processed: TAB008 is a bevacizumab biosimilar self-developed by TOT BIOPHARM for treating malignant tumors including advanced, metastatic and recurrent NSCLC and metastatic colorectal cancer. The new drug application (NDA) of TAB008 was filed in September 2020 and currently being processed by NMPA, which completed an on-site inspection and GMP-compliance inspection in January 2021. the Group expects to receive approval for marketing of the drug by end of 2021. As bevacizumab covers a number of cancers common in China, market demand would be huge.-- TAA013 - Smooth Progress of Phase III Clinical Trial: TAA013 is an ADC candidate containing trastuzumab and an emtansine derivative (Trastuzumab-MCC-DM1) for treating advance-stage or metastatic HER2+ breast cancer which could not be cured by trastuzumab and be surgically removed. In July 2020, the drug was given to the first patient in the Phase III clinical trial. To date, over 70 clinical research centers in the country are involved in the Phase III clinical trials making satisfactory progress.Key milestones of commercial production planning-- In the first half of 2021, TOT BIOPHARM actively deployed for ADC pilot production and commercial production. It has put together highly competitive GMP-compliant pilot production facilities for mAb and ADC liquid formulation and drug substance, including the OEB-5 potency-level freeze-dried powder/liquid injection formulation (Capacity of ADC drug substance: 1g~300g/batch; Capacity of ADC formulation line: 500~5,000 vials/batch) and a GMP-compliant ADC commercial production workshop (Capacity of ADC drug substance: 1,000g-3,000g/batch; Capacity of ADC formulation line: 10,000~15,000 vials/batch).Prominent Competitiveness of ADC DrugsTOT BIOPHARM possesses core conjugation process technologies, a complete ADC analysis technology platform and independent analysis capabilities in respect of ADC critical metric attributes. Accordingly, we have achieved technical breakthroughs in the regulation of glycoforms, enabling precise control of the composition of each glycoform. It attributes to ensure the successful development of ADC processes and produce high quality of products.TOT BIOPHARM has established an expert team for the R&D of conjugation process technologies of ADCs and an analysis team for complex ADC molecule structure. Boasting their extensive practical experience, successful exemplary cases and their comprehensive experience ranging from R&D, process development, clinical trials, registration and filing for approval to commercial production, and our products are at the leading position among ADCs in China.CDMO/CMO BUSINESS ACHIEVES LEAPFROG BREAKTHROUGHDevised One-stop Innovative Drug CDMO SolutionDespite the intense competition in the biomedical sector, TOT BIOPHARM has been able to effectively seize market opportunities and by giving full play to its open technological platform and commercial production capability, it has speeded up development of its "one-stop, localized" CDMO/CMO business, particularly in the ADC sector. It is able to capture first opportunities in the market and secure cooperation opportunities.-- TOT BIOPHARM owns core conjugation process technologies and has the ability to scale up technologies. With that advantage and capable of independent analysis of ADC critical metric attributes, the Group can guarantee the high quality of its product R&D work.-- It possesses "perfusion-batch hybrid technology" that can support commercial production of mAb drugs, including scaling up production from 25L to 2,000L directly, helping simplify the production process and shorten the production cycle, in turn enhance markedly the economic return of commercial CDMO/CMO projects.-- Priding long-term trusting relationship with partners, the Group took on various new CDMO/CMO projects in the first half of 2021, and saw substantial increase in terms of number of partners and business scale with the relevant revenue recording a substantial year-on-year growth of 330%.-- Being able to complete all the stages from R&D to putting out the end products in one plant and one place within the same production base at its Suzhou headquarter, TOT BIOPHARM managed to reduce much of the risks and difficulties in management, transportation and technological from outsourcing different procedures to different suppliers.Strengthened Cooperation and ExchangeTOT BIOPHARM cherishes its long-term relationship and various kinds of cooperation with diverse partners and aiming to enhance core competitiveness of CDMO services.-- On 19 July, TOT BIOPHARM and BrightGene Bio-Medical Technology Co., Ltd. (688166.SH) became strategic cooperation partners, which has seen its one-stop for ADC drug CDMO service platform strengthen in favor of R&D and commercialization of innovative drugs. Pursuant to the agreement, the two parties will work together to provide clients with services starting with development of production craftsmanship, moving on to scaling up production and eventually GMP-compliant production. The cooperation realized seamless connection of industrial chains, removing the risks from cross-regional regulation, and is a marriage of strengths in terms of technologies and resources, allowing further upgrade of the CDMO service platform for ADC drugs to provide one-stop solutions to innovative drug corporations to help them reduce R&D risks and make commercialization more efficient.CORE BUSINESS ADVANTAGESTOT BIOPHARM has developed three core business advantages, providing a solid foundation for development of and cooperation in relation to innovative drugs.-- Three Technology Platforms and Comprehensive Industrial Value Chain TOT BIOPHARM has three integrated technology platforms and a proven international quality Management and Registration System and registration team, plus a comprehensive industrial value chain that covers from R&D, process development, clinical trials, registration and filing to commercial production, giving it a solid foundation to speed up R&D, lay out international market presence and for its for its CDMO/CMO business.-- A Packed Product Pipeline with Huge Market PotentialAt present, the Group has 12 drug candidates in the pipeline, including monoclonal antibody drugs such as TAB008 (anti-VEGF mAb), TAB014 (anti-VEGF mAb) and TAY018 (anti-CD47 mAb), and ADCs such as TAA013 (anti-HER2 ADC), for indications involving various high incidence cancers, such as non-small-cell lung cancer, breast cancer, gastric cancer, cerebral gliomas cancer and cervical cancer.-- Rare Capability of Commercially Producing mAb and ADCAgreeing with the industrial upgrade of the Company and to meet market demand, the Group kicked off effort to expand production capacity in 2021, continuing to bolster the commercial production capacity of its antibody drugs and ADC products to prepare for the continuous expansion of the CDMO/CMO business. According to our strategic plan, we will keep on expanding our production capacity of mAb drugs to more than 16,000L. Future DevelopmentDr. Liu Jun, Chief Executive Officer, Chief Science Officer and Executive Director of TOT BIOPHARM, said, "We expect TAB008, our first biological drug, to be approved for launch to market in 2021, hence we will corporate with sizable pharmaceutical plants to roll out our marketing plan. At the same time, we will push forward clinical procedures of ADC TAA013 to enrich the ADC product pipeline. With biological drug CDMO business in China at large booming, leverage on our advantage of "one-base" CDMO/CMO value chain, we will allocate our resources to optimize CDMO business in ADC field, strengthen our brand image as well as consolidate our market position. "Looking ahead, we believe the competitive advantages of TOT BIOPHARM will become more and more obvious. We will keep presenting employees with ample room for development, and to our partners, with the best strategic solutions, and for shareholders, create value."FINANCIAL HIGHLIGHTS (as at 30 June 2021)Hong Kong Financial Reporting Standards Measures:-- Revenue was RMB23.132 million, representing a year-on-year growth of 78% thanks to the Group's proactive expansion of CDMO/CMO business heeding market changes, with relevant revenue up year-on-year growth by a substantial 330%.-- R&D expenses were RMB88.749 million, representing a year-on-year decrease of 11%, mainly attributable to the completion of Phase III clinical trials for the TAB008 project in the second half of 2020, which resulted in a year-on-year decrease in costs of clinical trials, also, R&D work completed for the TOZ309 project, there was a significant reduction of relevant expenses on R&D consumables. -- Selling expenses were RMB11.202 million, representing a year-on-year decrease of 18%, mainly attributable to the Company's sales strategy adjustments, resulting in reduction of relevant costs and expenses. -- General and administrative expenses were RMB26.823 million, representing a year-on-year increase of 11%, mainly attributable to the increase in operating and management expenses related to related to employee, administration and taxation, etc..-- The above mentioned all in account, net loss of the Group for the first half of 2021 reached RMB115.005 million, representing a year-on-year decrease of 11%. Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

23 6 月, 2021

Woven Alpha Automated Mapping Platform and Mitsubishi Fuso Collaborate on Latest HD Mapping Technology for Advanced Driver Assistance Systems Functionality

TOKYO, Jun 23, 2021 - (JCN Newswire via SEAPRWire.com) - Woven Alpha, Inc. ("Woven Alpha"), a group company of Woven Planet Holdings, Inc. ("Woven Planet"), a subsidiary of Toyota Motor Corporation ("Toyota"), has agreed to collaborate with Mitsubishi Fuso Truck and Bus Corporation ("MFTBC") to explore and advance safety for Advanced Driver Assistance Systems ("ADAS") with its Automated Mapping Platform ("AMP"). The initiation of this relationship between Woven Alpha and MFTBC marks another cross-industry collaboration with a commercial vehicle manufacturer outside the Toyota Group. Together the companies are conducting both lab-based and field test research for the development and deployment of improved safety functionality.This collaboration will explore the technical requirements of using AMP with MFTBC ADAS as well as the advantages of using AMP high definition ("HD") maps over conventional maps. Between the two companies, over 10 distinct use cases have been identified. The first Proof of Concept ("PoC") will focus on the application of AMP to provide an accurate Entering Curve Speed Warning ("ECSW") developed by MFTBC using their heavy-duty Super Great trucks. The results of this research will set the baseline for one of the ADAS performance upgrades available for commercial vehicles. This technology will help open up more exciting opportunities for collaboration with users and vehicle manufacturers outside the Toyota Group who are interested in taking advantage of enhanced mapping information to fully realize ADAS and automated driving functionality in their vehicles.Collaboration between Woven Alpha and MFTBC with AMPOverviewThe traditional solution for safety systems that use mapping technology has been to leverage navigation maps due to their relatively low cost. However, the lack of real-time updates means these maps are usually months out of date which can be dangerous for vehicles with higher levels of autonomy. In addition, their low accuracy in the order of meters makes it difficult to develop precise applications that operate safely at the lane level. Navigation maps also do not contain semantics, in other words, the relationship between road objects, such as between lanes on a road. Additionally, while it is relatively straightforward to deploy survey vehicles to generate the initial mapping data, the instruments are highly specialized and often expensive to operate. This leads to map maintenance being costly and time-consuming, further reducing the updates that can be deployed economically to end-users.However, the real world does not stand still. Regular changes to road markings, road geometry, or structural changes resulting from construction need to be reflected quickly into the HD maps in order for ADAS and automated driving functions to operate safely. AMP has been developed to solve these issues by automating the fusion of near real-time data from vehicle fleets and wide area coverage satellite and aerial imagery and dramatically improving map update frequency, coverage, and cost.Supporting MFTBC's ECSW feature is a great example of AMP providing immediate benefit to driver and vehicle safety. As part of the first PoC, both companies will test this feature that predicts the safest speed and gives advanced warning on how to approach an upcoming sharp curve, based on the vehicle's condition. The ability of the system to anticipate road and lane conditions ahead is particularly important for commercial vehicle drivers in order to avoid accidents. Through high-accuracy, low-cost, and up-to-date semantic HD maps, AMP aims to provide significantly improved driver awareness, system redundancy, and overall road safety.Comment from Mandali Khalesi, Vice President of Automated Driving Strategy and Mapping, Woven Planet"I am delighted to collaborate with Mitsubishi Fuso Truck and Bus Corporation, one of the leading truck and bus makers in Japan, perfectly suited to push the envelope on the safety of commercial vehicles. Our work is not only about getting people and goods from A to B, it is about saving people's lives and reducing the burden on the driver. Over the last few years, we have been working on developing highly accurate semantic HD maps updated automatically, frequently, and inexpensively. We are building the platform to be highly scalable and open to future collaboration with global manufacturers of all sizes. This is the first step in our commitment to helping maximize safety for commercial vehicles."Comment from Hironobu Ando, Senior Vice President, Head of Product Engineering, MFTBC"We at MFTBC approach automated driving assistance technology, and the autonomous driving technology beyond that, as a strategic point of focus in producing safer commercial vehicles. We are doing the utmost to develop these technologies, because we believe that they will soon be indispensable in our world. Woven Alpha's AMP has the potential to be an important part of this future, and we are therefore convinced that the joint research will prove to be mutually beneficial. We hope to participate in active knowledge-sharing with our partners to the maximum extent possible, for the ultimate goal of safer roads everywhere."About Woven Planet GroupWoven Planet Group (Woven Planet) represents a carefully curated blend of expertise and resources dedicated to bringing the vision of "Mobility to Love, Safety to Live" to life. Through innovations and investments in automated driving, robotics, smart cities, and more, we are transforming how humankind lives, works, and moves. We exist to design, build, and deliver secure, connected, and sustainable mobility solutions that benefit all people worldwide. Founded in 2018 as Toyota Research Institute - Advanced Development (TRI-AD), Woven Planet is comprised of four complementary companies: Woven Planet Holdings, Woven Core, Woven Alpha, and Woven Capital.For more information, please visit: https://www.woven-planet.global/MFTBC at a GlanceBased in Kawasaki, Japan, Mitsubishi Fuso Truck and Bus Corporation (MFTBC) is one of Asia's leading commercial vehicle manufacturers, with 89.29% of its shares owned by Daimler Truck AG and 10.71% by various Mitsubishi group companies. An icon in the Japanese commercial vehicle industry with a longstanding history of more than 85 years with its Fuso brand, MFTBC manufactures a range of commercial vehicles including light, medium, and heavy-duty trucks and buses, and industrial engines for over 170 markets worldwide. In 2017, MFTBC introduced the eCanter, the first all-electric light-duty truck in series-production and in 2019, the Super Great--Japan's first heavy-duty truck fitted with Level 2 Automated Driving Support Technology, a benchmark in the Japanese commercial vehicle market. MFTBC operates under the umbrella of Daimler Trucks Asia, together with its partner organization Daimler India Commercial Vehicles (DICV) in India. This strategic unit allows the entities to collaborate on areas such as product development, parts sourcing and production to provide the best value to customers.Contact:Woven Planet Holdings, Inc.Public Relationspr@woven-planet.globalhttps://www.woven-planet.global/ Copyright 2021 JCN Newswire. All rights reserved. (via SEAPRWire)

23 6 月, 2021

Fujitsu Demonstrates High Performance Simulations for Industrial Use Cases with Commercial Applications on the World’s Fastest Supercomputer, Fugaku

TOKYO, Jun 23, 2021 - (JCN Newswire via SEAPRWire.com) - Fujitsu Limited successfully leveraged on the world's fastest supercomputer, Fugaku, to demonstrate the feasibility of high performance, large-scale, very high-definition analyses with commercial applications widely used in the industrial field for simulations including fluid dynamics. The trials were conducted in collaboration with a number of application vendors between November 2020 and May 2021. Fujitsu and the participating vendors have additionally collaborated to validate operations and conduct performance tuning for commercial applications in high demand with manufacturers for Fugaku as well as the Fujitsu Supercomputer PRIMEHPC series, which draws on technology developed for the Fugaku project. Application vendors will begin to offer these commercial applications starting in June 2021.Going forward, Fujitsu will continue to validate commercial applications using its PRIMEHPC series and will market these to manufacturers and other companies engaged in product development and technical research, contributing to the development of the industrial field as a whole.BackgroundRecently, companies in areas including the manufacturing industry increasingly rely on commercial applications for x86 cluster systems (1) to perform simulations including fluid dynamics and structural analysis in product development and technical research. However, the growing demand for increasingly complex simulations presents challenges for users requiring rapid calculation results. The availability of these kinds of commercial applications used as is on supercomputers like Fugaku and Fujitsu's PRIMEHPC series, which boast large-scale, high-speed computing capabilities, could offer many potential benefits by allowing companies to continue using already-familiar applications and make use of their industry and process-specific expertise.To expedite the availability of these kinds of commercial applications, Fujitsu has provided a number of application vendors with development environments and testing environments for the PRIMEHPC series, working alongside these vendors. In large-scale simulations, Fujitsu analyzed the performance of commercial applications, did performance tuning to eliminate bottlenecks and applied parallel processing technology so that they could run efficiently with highly parallel processing. As a result, Fujitsu has successfully verified the operation of eight commercial applications. Fugaku was used for three of these applications to obtain high-speed, high-definition simulation results for large-scale analysis.Verification and results of large-scale analysis using commercial applicationsIn collaboration with various vendors, Fujitsu conducted a large-scale, high definition simulation for improving the energy efficiency and safety of aircraft and automobiles, which represents an increasingly important priority from the viewpoint of reducing environmental impact making use of commercial applications that have been tested for the PRIMEHPC series. Using the computing resources of Fugaku (2), Fujitsu conducted simulations with highly parallel processing, validating the feasibility of performing analyses within the amount of time required by companies for practical application in the real-world.1. Improvement of aircraft safetyDuring flight, an aircraft may experience a vibration phenomenon called buffet, which affects its safety and flight stability. Predicting buffet vibration is an important issue for aircraft safety design. This time, by executing the thermal fluid analysis application Cradle CFD | scFLOW (3) in parallel using the maximum possible 192,000 out of Fugaku's total number of CPU cores (4) of Fugaku and analyzing a high-definition model of 237 million elements with LES (5), which is an analysis method capable of expressing fine vortexes, it was possible to observe a phenomenon whereby pressure vibration and fine vortexes are generated on the surface of the blade. This makes it possible to predict the buffet effect in greater detail than the conventional RANS (6) analysis method using a coarse calculation grid. This proved that large-scale analyses leading to the safe design of aircraft taking into account the buffet could be calculated.2. Improvement of energy efficiency of automobile enginesImproving the energy efficiency of engines is an important issue for improving the fuel efficiency and environmental performance of automobiles. A combustion analysis that takes into account a series of chemical reactions, such as combustion inside a cylinder caused by piston action in the engine, was performed in two hours with parallel calculation using the thermal fluid analysis application CONVERGE (7) using up to 4,620 CPU cores of Fugaku's cores. In this analysis, the entire region was divided by a high-precision calculation grid (up to 6.67 million grids) of 0.5 mm units, and the use of LES made it possible to successfully obtain high-precision results showing a wrinkled flame structure, which would prove difficult with conventional RANS analysis. As a result, highly accurate analysis can be performed even during the limited time required for design work in the manufacturing industry, which is expected to lead to improvements in engine energy efficiency and reductions in abnormal combustion.3. Reduction of energy loss in driving motors for electric vehiclesTo improve the energy efficiency of electric and hybrid vehicles, it is necessary to reduce energy loss in the driving motor. One of the methods to calculate the loss generated by IPM motors (8) used in electric vehicles, etc., with high accuracy is to model the steel sheet of the iron core constituting the motor one by one, and to use the method to input the current containing harmonics. Conventional x86 clusters require several weeks to complete the calculation, but using Fugaku's 8,192 CPU cores and running them in parallel in the electromagnetic field analysis application JMAG (9), it can be done in a day (10). As a result, it is expected that analysis leading to improved energy efficiency in electric vehicles can be performed in a shorter time.Commercial applications to be verified operations on Fugaku and PRIMEHPC FX1000By providing vendors with development environments and technical support for Fugaku and PRIMEHPC FX1000, Fujitsu and application vendors have collaborated to newly validate operations for eight commercial applications, beginning with the structural analysis application LS-DYNA from Ansys (11), which is widely used in the manufacturing industry to improve collision safety for automobiles. Application vendors will begin to offer these commercial applications starting in June 2021.Future PlansFujitsu will continue to validate the operation of commercial applications for the PRIMEHPC series to meet the unique, real-world demands of its customers across a variety of industries, including manufacturers and other companies engaged in product development and technical research that want to conduct large-scale, high-definition simulations. Leveraging its industry-leading capabilities in high performance computing and its applications, Fujitsu will continue to contribute to the active development and innovation of technology development and research.Comments from Mr. Makoto Shibahara, President of Software Cradle Co., Ltd.Thanks to the efforts of Fujitsu Limited, we have confirmed that our thermal fluid analysis software can be used on the supercomputer Fugaku through this verification. Cradle CFD has been used in a wide range of industries for nearly 40 years, demonstrating the importance of large-scale computing resources in the field of thermo-fluid analysis, and this validation is a major milestone for us. This verification marks a major milestone in the field of thermal fluid analysis, and we believe that the use of Fugaku and our products will enable us to challenge the world's leading supercomputers, which were previously thought to be impossible. As part of the Hexagon Manufacturing Intelligence Group's efforts, we plan to offer Cradle CFD to the general public for use with Fugaku and Fugaku equivalent computing environments.Comments from Siddharth Shah, Principal Product Manager, AnsysAnsys is excited to announce the support of LS-DYNA for Fugaku and PRIMEHPC series hardware. LS-DYNA is widely used for its multi-physics capabilities including crash simulations which often requires high computational power. Ansys looks forward to working in close cooperation with Fujitsu to bring to market LS-DYNA for the PRIMEHPC series. Ansys is working to bring other flagship technologies such as Fluent to support Fujitsu PRIMEHPC series in the near future.(1) x86 cluster systems:A computer system configuration that connects multiple x86 servers for parallel processing.(2) Using the computing resources of Fugaku:This research was carried out by receiving the computational resources of the supercomputer Fugaku of RIKEN through the HPCI System Utilization Research Project (Issue No.: hp200209, hp200302).(3) Cradle CFD | scFLOW:Thermal fluid analysis software developed by Software Cradle Co., Ltd. https://www.cradle-cfd.com/product/scflow.html(4) CPU Cores:The Fugaku and PRIMEHPC series have 48 CPU cores of operation per node (1 CPU).(5) LES:Abbreviation for Large Eddy Simulation. A method of fluid analysis. It is possible to calculate even a fine vortex structure, but it requires a fine computational cells to express a fine vortex structure, and the calculation time is long.(6) RANS:Abbreviation for Reynolds-averaged Navier -- Stokes equations. A method of fluid analysis. This is a method commonly used in the industrial world because even a rough grid can be calculated and the calculation time can be shortened, but it cannot express complicated phenomena such as fine vortices.(7) CONVERGE:Thermal fluid analysis software developed by Convergent Science. The distributor in East Asia is IDAJ Co., Ltd. https://convergecfd.com/(8) IPM Motors:Embedded structure permanent magnet (Interior Permanent Magnet) synchronous motor.(9) JMAG:Electromagnetic field analysis software developed by JSOL Corporation for the design and development of electrical equipment. https://www.jmag-international.com/(10) Done in a day:Previously, it took several weeks to perform the calculation in 100 parallel, which is often performed in the industry, but it was shortened to one day by 8,192 parallel calculations using Fugaku. Note that 8,192 parallelism exceeds the maximum number of parallelism that has been calculated in JMAG.(11) LS-DYNA from Ansys:A structural analysis software developed by Ansys. The system has been provided to some customers in advance for PRIMEHPC FX1000, and operation verification was also conducted for Fugaku. General availability will begin from June. https://www.ansys.com/products/structures/ansys-ls-dyna(12) Explicit Method:An analysis method that directly (explicitly) solves equations that represent the motion of an object. It is suitable for problems in which large deformation and destruction occur instantaneously and is widely used in the manufacturing industry for uses cases including crash analysis of automobiles and fall analysis of electronic devices.(13) Implicit Method:An analysis method that indirectly (implicit) solves equations that represent the motion of an object. It is suitable for problems in stamping simulation or strength of static structures like a building, etc.Fujitsu's Commitment to the Sustainable Development Goals (SDGs)The Sustainable Development Goals (SDGs) adopted by the United Nations in 2015 represent a set of common goals to be achieved worldwide by 2030. Fujitsu's purpose -- "to make the world more sustainable by building trust in society through innovation"--is a promise to contribute to the vision of a better future empowered by the SDGs.About FujitsuFujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Approximately 126,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$34 billion) for the fiscal year ended March 31, 2021. For more information, please see www.fujitsu.com. Copyright 2021 JCN Newswire. All rights reserved. (via SEAPRWire)

15 6 月, 2021

Vodafone names NEC as a key partner for 5G massive MIMO radio units supporting commercial deployment of Open RAN in the UK

TOKYO, Jun 15, 2021 - (JCN Newswire via SEAPRWire.com) - NEC Corporation (TSE: 6701) announced today that it has been named as a key partner by Vodafone in the UK for supplying 5G massive MIMO radio units (RU) for the operator's initiative to build one of the largest commercial Open Radio Access Networks (RAN) in the world. Following Vodafone's announcement of its plan to initially deploy Open RAN to 2,500 sites in the UK, starting this year, the operator will work with key vendors to extend 4G and 5G coverage in rural areas in the South West of England and most of Wales, later moving into urban areas. NEC will be responsible for supplying its industry-leading massive MIMO 5G radio units that are compatible with the O-RAN Alliance 7-2x split. NEC will utilise its advanced technologies, commercial deployment experiences in Japan and its Open RAN Center of Excellence (CoE) in the UK to support Vodafone's Open RAN deployment. "Open RAN is essential to accelerating innovation and increasing supply chain diversity," said Johan Wibergh, Chief Technology Officer, Vodafone. "Vodafone is keen to work with our strategic partners such as NEC to create a more cost-effective, secure, energy efficient and customer-focused network of the future.""NEC is delighted to be awarded this project and we are excited to be working with Vodafone on this strategically important initiative," said Shigeru Okuya, Senior Vice President, NEC Corporation. "We look forward to accelerating the development of Open RAN systems which in turn will improve innovation and help drive the UK digital economy."NEC is also actively engaged in NeutrORAN, which demonstrates Open RAN ecosystem-based neutral host solutions. This is a part of the 5G testbed and trials program initiated by the UK Government in order to improve telecom supply chain diversification.Reference:Vodafone's Press Release (14 June 2021)new windowVodafone selects key partners to build Europe's first commercial Open RAN networkAbout VodafoneVodafone is a leading telecommunications company in Europe and Africa. We are the largest mobile and fixed network operator in Europe and a leading global IoT connectivity provider. Our M-Pesa technology platform in Africa enables over 48m people to benefit from access to mobile payments and financial services. We operate mobile and fixed networks in 21 countries and partner with mobile networks in 49 more. As of 31 March 2021, we had over 300m mobile customers, more than 28m fixed broadband customers, over 22m TV customers and we connected more than 123m IoT devices. https://www.vodafone.com/About NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com. Copyright 2021 JCN Newswire. All rights reserved. (via SEAPRWire)

4 5 月, 2021

China Dynamics Strategically Invests in Germany’s Quantron AG

HONG KONG, May 4, 2021 - (ACN Newswire via SEAPRWire.com) - China Dynamics (Holdings) Limited (the "Company"; Stock Code: 476, together with its subsidiaries, collectively "China Dynamics" or the "Group"), which provides new energy vehicles and technology integrated solutions, has entered into an investment agreement with Quantron AG ("Quantron"), a Germany-based company engaged in e-mobility in inner city and regional passenger and freight transport.Centre: Mr. Miguel Valldecabres Polop, CEO of China Dynamics, believes that the investment agreement with Quantron will bring forth synergistic benefits to the Group. Left: Mr. Michael Perschke, a member of Quantron's supervisory board and an International Advisor at China Dynamics. Right: Mr. Andreas Haller, Chairman of the board of Quantron.Under the agreement, the Group has conditionally agreed to subscribe to 2,698 Quantron subscription shares, representing approximately 4.98% of the latter's enlarged share capital.Quantron is expected to source e-vehicles components and retrofitment kits from China Dynamics to meet demand from its customers and to explore opportunity with the Group for joint development of light and medium e-delivery trucks.Mr. Miguel Valldecabres Polop, CEO of China Dynamics, said, "With its long-standing electric vehicle ("EV") expertise in commercial vehicles and its great market access in Europe, Quantron is an ideal fit into our group of EV-focused companies and it will become the Group's key gateway to Europe. China Dynamics and Quantron will explore opportunities in EV light and medium delivery trucks - a segment in which Quantron is already hugely successful with its electrification of the large light commercial van IVECO Daily."Mr. Andreas Haller, Chairman of the Board of Quantron AG, said: "China Dynamics will play an important part of our global growth strategy with its supply of retrofitment components as well as provision of engineering support and hydrogen-powered commercial vehicles. Meanwhile, Quantron will explore sourcing and supply chain opportunities with China Dynamics for EV components and retrofitment kits, based on the new regulation and subsidies to be released by the German Government in Q2/2021."China Dynamics and Quantron have also confirmed the appointment of Mr. Michael Perschke as a member of Quantron's supervisory board. Mr. Perschke is part of China Dynamics' Team of International Advisors who support the Group's growth strategy in the global market.About China Dynamics (Holdings) Limited (Stock Code: 476)China Dynamics (Holdings) Limited is a pioneer and a prominent player in China's new energy commercial vehicles market, as well as a whole-vehicle manufacturer of specialty passenger vehicles and new energy passenger vehicles. It is an integrated driving and logistics solutions provider with a solid technological foundation in diverse areas including new energy platform power system and its key components. The Group has production base in Chongqing and it has developed its sales network in Mainland China, Hong Kong, Asia Pacific and South America. To better reflect the Group's business and its development direction to globalise its electric vehicles to world markets, the Company has proposed to change its name to "EV Dynamics (Holdings) Limited".About Quantron AGQuantron AG is a system provider of clean battery and hydrogen-powered e-mobility for commercial vehicles such as trucks, buses and vans. In addition to new electric vehicles, the wide range of services offered by the innovation forge includes the electrification of used and existing vehicles, the creation of individual overall concepts including the appropriate charging infrastructure as well as rental, financing and leasing offers and driver training. Quantron AG also sells batteries and integrated customised electrification concepts to manufacturers of commercial vehicles, machinery and intralogistics vehicles. The German company from Augsburg in Bavaria is a pioneer and innovation driver for e-mobility in passenger, transport and freight traffic.Media EnquiryStrategic Financial Relations LimitedVicky Lee, +852 2864 4834, vicky.lee@sprg.com.hkPhoebe Leung, +852 2114 4172, phoebe.leung@sprg.com.hkEddie Li, +852 2114 4170, eddie.li@sprg.com.hkWebsite: www.sprg.com.hkQuantron AGVolker Seitz, 0049-821-789840-86, press@quantron.net Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

24 3 月, 2021

TOT BIOPHARM Announces A Number of Key Anti-Tumor Drugs Have Entered the Pivotal Clinical Stage in 2020

HONG KONG, Mar 24, 2021 - (ACN Newswire via SEAPRWire.com) - TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Company"; stock code: 1875.HK), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs and therapies, announced today its audited annual results for the year ended 31 December 2020.Milestones of 2020 Annual Results TOT BIOPHARM's core products including mAb drug TAB008 and ADC drug TAA013 have achieved key milestones. The Company actively promoted the development of and collaboration relating to innovative drugs and have established a R&D and commercialization platform integrating mAb and ADC drugs. The Company will rapidly expand its CDMO/CMO business to create new momentum for the future development of the Company.Key milestones of pipeline products: -- TAB008 (anti-VEGF mAb): Phase III clinical results were published. The clinical results show that TAB008 has similar efficacy, safety, immunogenicity and pharmacokinetics profiles with the brand-name formulation of bevacizumab. The new drug application under the new version of the Administrative Measures for Drug Registration was submitted, and was accepted by NMPA in September 2020 (Note: Pre-approval registration inspection was completed in January 2021). It is expected to be approved for marketing in 2021. -- TAA013 (anti-HER2 ADC): It is the first T-DM1 ADC product entering Phase III clinical trial in China. The first participant was enrolled in July 2020. Clinical recruitment is progressing smoothly.-- TAB014 (anti-VEGF mAb): Phase III clinical trial application (IND) was submitted to FDA. Upon receiving FDA's approval, it would be exempted from the Phase II clinical trial and would directly carry out Phase III clinical trial (Note: (IND authorized by FDA in January 2021, and would directly carry out Phase III clinical trial).-- TOZ309 (temozolomide capsule): Pre-approval registration inspection was completed, and it is expected to be approved for marketing in the first half of 2021.Key milestones of commercial production plans-- In 2020, the construction of the ADC drug substance commercial production facility was completed, and the production of multiple batches of ADC drugs for clinical purposes was accomplished.-- In 2020, the GMP compliance inspection of the production workshop for chemical drugs was completed, laying a foundation for the commercial production of chemical drugs.Dr. Liu, Jun, Chief Executive officer, Chief Scientific Officer, and Executive Director of TOT BIOPHARM, said, "TOT BIOPHARM has achieved multiple targets during the year, and manifested more prominent competitive and it has gradually formed a trend of coordinated development for R&D and commercial production of innovative drugs. In 2020, our R&D achievements are encouraging! The core product TAB008, TOT BIOPHARM's Independently developed bevacizumab biosimilar, has been submitted new drug application under the new version of the Administrative Measures for Drug Registration, and has been accepted by NMPA. Moreover, ADC drug TAA013 has successfully entered Phase III clinical trial, with a leading position in China in terms of our R&D progress. In the meantime, TOT BIOPHARM has established a R&D and commercialization platform integrating monoclonal antibodies (mAb) and antibody drug conjugates (ADC). In short, medium and long-term development, we will continue to enhance its production capacity planning and expand its CDMO/CMO business, so as to meet international and domestic clinical and commercial needs, and create new momentum for the future development of the Company. 2021 will be a fruitful year for TOT BIOPHARM, our core products TAB008 and chemical drug TOZ309, are expected to be approved for marketing, thereby benefiting a large number of cancer patients. We will continue to commit on our corporate vision of improving the quality of life of cancer patients worldwide with innovative technologies through the unremitting efforts."Unique Business Models-- Our three integrated technology platforms and comprehensive industry chainWith three self-developed technology platforms and a complete international quality management system and registration team, TOT BIOPHARM has a comprehensive industry chain, covering from drug research and development, clinical research to commercial production, which lays a foundation for accelerating the progress of R&D, international market plan and CDMO business.-- Abundant Product PipelineAt present, we have 13 drug candidates, including biological drugs, TAB008 (anti-VEGF mAb), TAB014 (anti-VEGF mAb) and TAY018 (anti-CD47 mAb), and antibody drug conjugates (ADC), TAA013 (anti-HER2 ADC), which are indicated for various cancers with high incidence, such as non-small-cell lung cancer, breast cancer, gastric cancer, esophageal cancer and cervical cancer.-- Commercial Production Layout with Competitive EdgeTOT BIOPHARM adheres to the business philosophy of the integration of innovative R&D and commercial production. The Company has a 16,000L capacity for mAb production and ADC drug substance production facility. In September 2020, the construction of drug substance production facility was completed for the commercial production of ADCs; the production workshop for chemical drugs has completed the GMP compliance inspection, which laid a foundation for the commercial production of chemical drugs.The operations of the Company's various R&D pipelines proceeded hand-in-hand in 2020 and achieved smooth progress with the following major milestones.Soon-to-be-commercialized Drugs-- TAB008 (anti-VEGF mAb) (Non-squamous non-small-cell lung cancer (nsNSCLC)): The new drug application was submitted under the new version of the Administrative Measures for Drug Registration, and was accepted in September 2020. It is expected to be marketed in 2021.-- TOZ309 (temozolomide capsules (200mg,100mg)): The temozolomide generic drug, a chemical drug, completed the pre-approval registration inspection, and it is expected to be marketed in the first half of 2021.-- TOM312 (megestrol acetate): We have completed the commercial-scale formulation process validation through continuous technological optimization, and have successfully submitted the ANDA application in Taiwan.Clinical Trial Progress and Achievement-- TAA013 (anti-HER2 ADC) (HER2-positive breast cancer): Phase III clinical trials were initiated in June 2020 with the first patient enrolled in July, and it is currently at the stage of clinical recruitment. It is planned to be launch in the market in 2023.-- TAB014 (anti-VEGF mAb) (wet age-related macular degeneration (wAMD)): We have completed the pivotal Phase III clinical trials and CDE consultation, and directly carried out the Phase III clinical trials exempting from the domestic Phase II clinical trials. At the same time, we submitted the investigational new drug (IND) in respect of the Phase III clinical trial application of TAB014, based on the data from the Phase I clinical trial of TAB014 conducted in China and relevant clinical literature data, this IND application is a direct application for authorization to conduct Phase III clinical trial (being exempted from Phase II clinical trial).-- TIC318 (carboplatin) (epithelial-derived ovarian cancer, small cell lung cancer, head and neck squamous cell carcinoma, testicular tumors, malignant lymphoma, cervical cancer, bladder cancer and NSCLC): We have completed commercial-scale formulation process validation in the high active drug injection workshop.Commercial Production and CDMO/CMO Strategic CollaborationTOT BIOPHARM increased resource investment, actively promoted CDMO/CMO business, and developed diversified strategic collaboration with domestic and foreign pharmaceutical companies to provide customers with high-standard and high-quality CDMO/CMO services.-- The Company's commercial production technology demonstrates a sharp competitive edge in cost effect. Its self-developed perfusion-batch combined process flows, PB-Hybrid Technology, can realize commercial production direct scale-up from 25L to 2,000L in the cell culture process, thereby streamlining process flows, reducing production risks while shortening production cycles, lowering production costs, and greatly improving production capacity and cost advantages.-- For the year of 2020, the Company has reached commercial collaboration with several innovative pharmaceutical companies to provide CDMO/CMO services for new drug R&D partners, including the CDMO collaboration with Kintor Pharmaceutical Limited (9939.HK) to continue providing clinical supplies manufacture and technical support for its core product Proxalutamide in China and the United States. At the same time, we provide Kintor clinical supplies manufacture for the novel coronavirus disease (COVID-19) overseas (including the United States, Brazil, etc.), pursues diversified collaboration opportunities while increasing the Company's cash flows.Future DevelopmentEmbrace openness and win-win collaboration to promote domestic and internationalcommercial collaboration for drug candidates: At present, TOT BIOPHARM has multiple product pipelines such as biological drugs, ADC drugs and chemical drugs, which are stepping into the commercial stage with huge market potential. TOT BIOPHARM has been adhering to the principle of openness, collaboration and win-win, and discusses future commercial development strategies with various domestic and foreign partners. Relying on R&D, clinical trials and a one-stop full industry chain platform of application, manufacturing and commercialization, TOT BIOPHARM actively seeks the strategic collaboration domestically and internationally. We will obtain milestone funds through the transfer of domestic and foreign sales rights. Through diversified collaboration models, we share resources, accelerate the progress of product R&D and marketing, and rapidly occupy domestic and foreign market shares to enhance market competitiveness. Leveraging our unique advantages in R&D and production, we strengthen CDMO/CMO business collaboration to provide pharmaceutical companies with production capacity and technological requirements which they are lack of, and help customers shorten production time and reduce production costs in a cost-effective manner.Financial Highlights-- Revenue amounted to RMB22,491,000, representing a 50% year-on-year decrease, mainly attributable to the impact of the national volume-based procurement policy on the sales derived from the distribution of brand-name drug S-1, and the alignment of our CDMO business with our customers' planned schedules.-- Research and development expenses amounted to RMB235,196,000, representing a 23% year-on-year increase, mainly attributable to the commencement of Phase III clinical trial for the TAA013 project of the Company in 2020 after the completion of Phase I clinical trial that resulted in an increase in demand for active pharmaceutical ingredients (APIs), excipients and consumables by related contract research (CROs) and those for the preparation of clinical drugs.-- Selling expenses amounted to RMB25,953,000, representing a 18% year-on-year decrease, mainly attributable to the overall economic slowdown as a result of the outbreak of COVID-19 in 2020 which led to the suspension or postponement of various marketing events.-- General and administrative expenses amounted to RMB46,855,000, representing a 51% year-on-year decrease, mainly attributable to the inclusion of listing expenses in the expenses for the same period in 2019.-- In summary, net loss for the year of 2020 amounted to RMB288,498,000, representing a 4% year-on-year decrease.About TOT BIOPHARM International Company Limited (Stock Code: 1875.HK)TOT BIOPHARM is dedicated to developing and commercializing innovative anti-tumour drugs and therapies, striving to build a leading brand of oncology treatments worthy of the trust of patients and their families, and medical professionals. The Company has in place three major integrated technology platforms. They are:Therapeutic Monoclonal Antibody and ADC Technology Platform: it integrates research and development (R&D) and production capacities for antibody-based drugs and ADC, with the designed production capacity of the commercialization base of biological drugs reaching 16,000L to accommodate high-quality commercialization of drug candidates; Gene Engineering Based Therapeutics Technology Platform: it integrates anti-tumour immunotherapy, gene therapy and viral therapy and pursues R&D and production of tumour-targeted oncolytic virus products;Innovative Drug Delivery Technology Platform: a comprehensive platform for the process development and commercial production of high intensity and frequency of drug injections. It adopts a production design with aseptic lyophilization and aseptic filling to satisfy the GMP production requirement of OEB 4/5 active level lyophilized powder and water needle.Using these platforms, the Company has studied and developed various anti-tumour drug series and genres, and has formed a high quality and comprehensive drug product chain. On top of developing innovative proprietary drugs, the Company also draws on its own industry value chain to build a complete industry chain platform that supports operations from R&D and production and clinical development to marketing. By adopting an open platform business model, it is able to cooperate with biomedical enterprises and third parties at different stages along its industry value chain.For enquiries:Strategic Financial Relations (China) LimitedAnita Cheung / Winnie Lau / Christina Chong / Tin TimTel: (852) 2864 4827 / 2864 4876/ 2864 4899 / 2114 4907Email: sprg-tot@sprg.com.hk Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)